Regencell Bioscience Holdings Limited (RGC) Q4 2025 earnings summary

Executive summary

• Focuses on research, development, and commercialization of TCM for ADHD and ASD, with no revenue generated to date and operations based in Hong Kong.

• Completed two efficacy trials showing reduced symptom severity in ADHD and ASD patients using a standardized TCM formula.

• Net losses for FY2025 and FY2024 were $3.58 million and $4.36 million, respectively, with substantial doubt about ability to continue as a going concern.

• Management is actively seeking additional financing and cost-saving measures to support ongoing operations.

Financial highlights

• No revenue generated for the years ended June 30, 2025 and 2024.

• Net loss of $3.58 million in FY2025, improved from $4.36 million in FY2024.

• Operating expenses decreased 20% year-over-year to $3.77 million in FY2025.

• Cash and short-term investments totaled $4.90 million as of June 30, 2025.

• Accumulated deficit reached $25.20 million as of June 30, 2025.

Outlook and guidance

• Expects to continue incurring operating losses and negative cash flows for the foreseeable future.

• Plans to commercialize TCM formula in Hong Kong after regulatory approval, then expand globally.

• Actively pursuing additional financing and cost-saving initiatives to enhance liquidity.